ABVC Biopharma Files 8-K for Shareholder Votes & Exhibits
Ticker: ABVC · Form: 8-K · Filed: Apr 19, 2024 · CIK: 1173313
| Field | Detail |
|---|---|
| Company | Abvc Biopharma, Inc. (ABVC) |
| Form Type | 8-K |
| Filed Date | Apr 19, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting
TL;DR
ABVC Bio filed an 8-K for shareholder votes and financials - check the exhibits for details.
AI Summary
ABVC Biopharma, Inc. filed an 8-K on April 19, 2024, to report on matters submitted to a vote of security holders and to file financial statements and exhibits. The filing does not contain specific details about the votes or the financial statements themselves within the provided text.
Why It Matters
This filing indicates that ABVC Biopharma has held or is reporting on votes by its shareholders and is submitting required financial documents, which are crucial for transparency and regulatory compliance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate actions and financial reporting, not indicating immediate operational or financial distress.
Key Players & Entities
- ABVC BIOPHARMA, INC. (company) — Registrant
- Nevada (jurisdiction) — State of incorporation
- 001-40700 (filing_id) — SEC File Number
- 26-0014658 (tax_id) — IRS Employer Identification No.
- 44370 Old Warm Springs Blvd. Fremont, CA 94538 (address) — Business and Mail Address
- American BriVision (Holding) Corp (company) — Former Company Name
- METU BRANDS, INC. (company) — Former Company Name
- ECOLOGY COATINGS, INC. (company) — Former Company Name
FAQ
What specific matters were submitted to a vote of ABVC Biopharma's security holders?
The provided text of the 8-K filing states that Item 5.07 is 'Submission of Matters to a Vote of Security Holders,' but the specific details of the matters voted upon are not included in this excerpt.
What financial statements and exhibits are being filed with this 8-K?
The filing indicates that Item 9.01 is 'Financial Statements and Exhibits,' but the actual content of these financial statements and exhibits is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on April 19, 2024.
What is ABVC Biopharma's state of incorporation and fiscal year end?
ABVC Biopharma, Inc. is incorporated in Nevada and its fiscal year ends on December 31.
Has ABVC Biopharma changed its name previously?
Yes, ABVC Biopharma, Inc. was formerly known as American BriVision (Holding) Corp, METU BRANDS, INC., and ECOLOGY COATINGS, INC., with name changes occurring on January 11, 2016, September 8, 2015, and August 21, 2008, respectively.
Filing Stats: 899 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2024-04-19 17:26:35
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ABVC The Nasdaq Stock Mar
Filing Documents
- ea020408501-8k_abvcbio.htm (8-K) — 40KB
- 0001213900-24-034583.txt ( ) — 208KB
- abvc-20240419.xsd (EX-101.SCH) — 3KB
- abvc-20240419_lab.xml (EX-101.LAB) — 33KB
- abvc-20240419_pre.xml (EX-101.PRE) — 22KB
- ea020408501-8k_abvcbio_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security
Item 5.07 Submission of Matters to a Vote of Security Holders. On April 16, 2024, ABVC BioPharma, Inc. (the " Company ") held its 2024 annual meeting of shareholders (the " Annual Meeting "), which was originally scheduled for January 16, 2024. At the Annual Meeting, the Company's shareholders voted on 4 proposals. At the beginning of the Annual Meeting, 5,736,015 shares of common stock, which represents 54.31% of the voting power of the shares entitled to vote at the Annual Meeting, were represented by proxy, which constituted a quorum for the transaction of business. We are filing this Current Report on Form 8-K to disclose the voting results from the Annual Meeting. 1. To re-elect 11 directors to the Company's board of directors (the " Board "), with such directors to serve until the 2025 annual meeting of shareholders. Name For Against Withheld Eugene Jiang 4,542,439 0 43,661 Dr. Tsang Ming Jiang 4,542,416 0 43,684 Norimi Sakamoto 4,542,773 0 43,327 Yen-Hsin Chou 4,542,416 0 43,684 Dr. Tsung-Shann (T.S.) Jiang 4,542,559 0 43,541 Dr. Chang-Jen Jiang 4,542,214 0 43,886 Hsin-Hui Miao 4,541,882 0 44,218 Yoshinobu Odaira 4,541,795 0 44,305 Che-Wei Hsu 4,541,882 0 44,218 Shuling Jiang 4,541,486 0 44,614 Yu-Min (Francis) Chung 4,542,178 0 43,922 Accordingly, all directors were re-elected. 2. To ratify the appointment of WWC P.C. CPA as the Company's independent registered public accounting firm for fiscal year ending December 31, 2024. For Against Abstain 5,449,292 123,503 163,220 Accordingly, WWC P.C. CPA was reappointed as the Company's independent registered public accounting firm for fiscal year ending December 31, 2024. 3. To authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock underlying convertible notes and warrants issued by us pursuant to the terms of that certain Securities Purchase Agreement dated February 23, 2023, a
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABVC BioPharma, Inc. April 19, 2024 By: /s/ Uttam Patil Uttam Patil Chief Executive Officer